Gen: Top 20 new companies in molecular diagnostics

Source: bioprospecting 2015-5-6 according to Kalorama, the molecular diagnosis industry is expected to grow to $7.6 billion by 2017, while grand view research also said that the molecular diagnosis industry will exceed $8 billion by 2020 Such an attractive prospect has attracted more and more large enterprises and small companies in this field The biggest players in the field include familiar Roche, Qiagen, BD, Abbott and some new players hologic, Grifols and bio m é Rieux Over the past few years, however, the field has brought together a large number of small companies focused on specific technology or disease areas In the past year alone, several small companies have been acquired; among them, Roche has undertaken a number of transactions Last April, Roche acquired iquum for 450 million dollars, followed by genia technologies for 350 million dollars in June, and ariasa diagnostics for 625 million dollars in December In 2015, Roche continued to hold high the banner of "small acquisition", and successively won the signature diagnostics, foundation medicine and CAPP medical In addition to the deals Roche has included, deals in the field of molecular diagnostics include Rosetta genomic's acquisition of personalized DX, bio m é Rieux's acquisition of biofire diagnostics, Myriad Genetics's acquisition of crescendo Bioscience and veracite's acquisition of Allegro diagnostics According to the annual revenues published by various companies in 2014, 20 new companies in the field of molecular diagnosis are listed as follows: special remarks: 1 Altheadx ranked No 8: the deadline of revenue report is September 30, 2014; 2 AutoGenomics ranked No 10: the deadline of net revenue report is June 30, 2014, 2013 The annual net revenue is USD 18.083 million 3 Genetic technologies ranked 14th: the data comes from the company's latest financial report, ending on July 1, 2014 4 HTG molecular diagnostics ranked 15th: the deadline for revenue report is September 30, 2014, with revenue of $2.243 million in 2013 5 Genetic signatures ranked 20th: the data is from the company's latest financial report, ending on June 30, 2014.